Boston Scientific Corp (BSX)

23.82
0.30 1.28
NYSE : Health Care
Prev Close 23.52
Open 23.49
Day Low/High 23.45 / 23.91
52 Wk Low/High 15.67 / 24.79
Volume 9.49M
Avg Volume 8.85M
Exchange NYSE
Shares Outstanding 1.36B
Market Cap 32.03B
EPS -0.20
P/E Ratio 470.40
Div & Yield N.A. (N.A)

Latest News

Boston Scientific Charts Appear Boston Strong

Boston Scientific Charts Appear Boston Strong

The technical signs indicate the stage may be set for new highs in the maker of medical devices.

Edwards' Life Goes On Without Big M&A

Edwards' Life Goes On Without Big M&A

As the dominant player in the transcatheter aortic valve replacement market, Edwards doesn't 'need' large deals.

How to Trade Wednesday's Most Active Stocks - Sprint, AMD, ArcelorMittal and More

How to Trade Wednesday's Most Active Stocks - Sprint, AMD, ArcelorMittal and More

Here's a technical look on how to trade some of the most active stocks on the market today.

Analysts' Actions -- Boston Scientific, McDonald's, National Beverage, More

Analysts' Actions -- Boston Scientific, McDonald's, National Beverage, More

Here are Monday's top research calls, including upgrades for McDonald's and National Beverage, and a downgrade for Boston Scientific.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AIT, DSPG, FCAU, FOGO, HFC, KLIC, LINK, MGLN, MOG.A, MOG.B Downgrades: BSX, DOC, FCE.A, FCE.B, ICCC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Boston Scientific Announces Agreement To Acquire Neovasc Advanced Biological Tissue Capabilities

Boston Scientific Announces Agreement To Acquire Neovasc Advanced Biological Tissue Capabilities

¿ $75M transaction enhances manufacturing expertise in structural heart

The Most Admired Corporate Dealmakers in a Record Year

The Most Admired Corporate Dealmakers in a Record Year

In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.

Boston Scientific Takes Over #76 Spot From Sherwin-Williams

Boston Scientific Takes Over #76 Spot From Sherwin-Williams

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Boston Scientific Corp. has taken over the #76 spot from Sherwin-Williams Co , according to ETF Channel.

Boston Scientific Closes EndoChoice Acquisition

Boston Scientific Closes EndoChoice Acquisition

Acquisition Expands Endoscopy Portfolio

Boston Scientific Announces Positive Results Of HeartLogic™ Heart Failure Diagnostic Service

Boston Scientific Announces Positive Results Of HeartLogic™ Heart Failure Diagnostic Service

Late-Breaking Trial Data Presented at AHA Scientific Sessions Demonstrate Success of Alert to Predict Worsening Heart Failure

Boston Scientific Acquires Resectr™ Tissue Resection Device From Distal Access, LLC

Boston Scientific Acquires Resectr™ Tissue Resection Device From Distal Access, LLC

Acquisition Advances Treatment Options for Women with Uterine Polyps

Boston Scientific Announces Acquisition Of The LumenR™ Tissue Retractor System

Boston Scientific Announces Acquisition Of The LumenR™ Tissue Retractor System

Technology to Improve Management of Gastrointestinal Diseases

Boston Scientific Announces Initial U.S. Commercial Performance Of The WATCHMAN™ Left Atrial Appendage Closure Device

Boston Scientific Announces Initial U.S. Commercial Performance Of The WATCHMAN™ Left Atrial Appendage Closure Device

Late-Breaking Trial Data Presented at TCT Scientific Sessions and Simultaneously Published in the Journal of the American College of Cardiology

Primary Endpoint From Study Of Drug Eluting Coronary Stent In Underserved Patient Populations Presented At TCT 2016

Primary Endpoint From Study Of Drug Eluting Coronary Stent In Underserved Patient Populations Presented At TCT 2016

The PLATINUM Diversity Study Provides Much Needed Data about Women and Minority Patients, Who are Under-represented in Cardiology Clinical Trials

'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says

'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says

Jim Cramer likes SWHC and BX, but not NAT and DBD.

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Cramer previews important earnings reports scheduled for the coming week.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARI, BA, BSX, PIH, SCCO, TER, TIF, VLRS Downgrades: AIT, KO, NWSA, POL, PPC, VEC Initiations: SMBK Read on to get TheStreet Quant Ratings' detailed report:

Boston Scientific Shares Flat Following Mixed Earnings Results

Boston Scientific Shares Flat Following Mixed Earnings Results

Boston Scientific reported earnings of $0.27, in-line with analyst expectations.

Boston Scientific (BSX) Stock Advances on Q3 Revenue Beat, Guidance

Boston Scientific (BSX) Stock Advances on Q3 Revenue Beat, Guidance

Boston Scientific (BSX) reported 2016 third-quarter revenue that exceeded analysts' expectations and raised its full-year revenue forecast.

Boston Scientific Remains Disciplined Buyer in Light of Large-scale Industry Consolidation

Boston Scientific Remains Disciplined Buyer in Light of Large-scale Industry Consolidation

The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.

What to Look for When Boston Scientific (BSX) Reports Q3 Earnings

What to Look for When Boston Scientific (BSX) Reports Q3 Earnings

Before Wednesday's market open Boston Scientific (BSX) will post 2016 third quarter results.

Boston Scientific Launches Resolution 360™ Clip

Boston Scientific Launches Resolution 360™ Clip

Launch of Hemostasis Clip Advances Innovation within the Field of Endoscopy